Month: February 2022

Just published in AJO: “Optical Coherence Tomography Anatomic and Temporal Biom…

Just published in AJO: https://t.co/3CP1ggDwGG “Optical Coherence Tomography Anatomic and Temporal Biomarkers in Uveitic Macular Edema”. This longitudinal modeling figure shows how anatomic precedes visual improvement after treatment for uveitic macular edema. #eye #retina https://t.co/Iw5VUjcikj Source by Thomas Ciulla, MD, MBA Return to main website.

RT @eyewireplus: .@REGENXBIO announced additional positive interim data from the…

RT @eyewireplus: .@REGENXBIO announced additional positive interim data from the ongoing phase 2 ALTITUDE trial of RGX-314 for the treatmen… Source by Thomas Ciulla, MD, MBA Return to main website.

Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprach…


Our recent paper was “Editor’s Choice”: This post hoc analysis compared #suprachoroidal triamcinolone acetonide (CLS-TA) to other treatments for macular edema due to #uveitis. https://t.co/iFbR8A7DG4


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @Ophthalmologymg: @BauschLomb’s Xipere therapy offers hope to patients with m…

RT @Ophthalmologymg: @BauschLomb’s Xipere therapy offers hope to patients with macular edema associated with non-infectious uveitis. By Kar… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @EvolveMedEd: Want to Know More About the Future of Suprachoroidal Injections…

RT @EvolveMedEd: Want to Know More About the Future of Suprachoroidal Injections? Come check out this #CME series featuring a new supplemen… Source by Thomas Ciulla, MD, MBA Return to main website.

Just presented “The Suprachoroidal Space and Suprachoroidal Delivery for Clinici…


Just presented “The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians” at #Angiogenesis2022, covering key features of #suprachoroidal delivery: targeting & compartmentalization, drivers of durability & posterior flow, therapies in development
#eye #retina https://t.co/WYLuN9eb4B


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @RetinaToday: The push for longer-acting therapeutics has garnered us several…

RT @RetinaToday: The push for longer-acting therapeutics has garnered us several long-duration corticosteroid therapies to choose from. Thi… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Looking forward to presenting “The Suprachoroidal Space and …

RT @ThomasCiullaMD: Looking forward to presenting “The Suprachoroidal Space and Suprachoroidal Delivery for Clinicians” at next week’s Angi… Source by Thomas Ciulla, MD, MBA Return to main website.

RT @ThomasCiullaMD: Honored to be recognized as a global expert in #maculardegen…


RT @ThomasCiullaMD: Honored to be recognized as a global expert in #maculardegeneration , a leading cause of irreversible vision loss: http…


Source by Thomas Ciulla, MD, MBA

Return to main website.

RT @RetinaGlobal1: Gene therapy, specifically designed to neutralize #VEGF activ…

RT @RetinaGlobal1: Gene therapy, specifically designed to neutralize #VEGF activity, may be the next approach to the treatment of #diabetic… Source by Thomas Ciulla, MD, MBA Return to main website.